• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Towards a tailored systemic therapy for liver cancer.

作者信息

Sacco Rodolfo, Facciorusso Antonio

机构信息

Gastroenterology Unit, University of Foggia, Foggia, Italy.

出版信息

Ann Transl Med. 2020 Oct;8(20):1327. doi: 10.21037/atm-20-3194.

DOI:10.21037/atm-20-3194
PMID:33209907
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7661866/
Abstract
摘要

相似文献

1
Towards a tailored systemic therapy for liver cancer.迈向针对肝癌的个体化系统治疗。
Ann Transl Med. 2020 Oct;8(20):1327. doi: 10.21037/atm-20-3194.
2
Centralization of Liver Cancer Surgery and Impact on Multidisciplinary Teams Working on Stage IV Colorectal Cancer.肝癌手术的集中化及其对从事IV期结直肠癌治疗的多学科团队的影响。
Oncol Rev. 2017 Jul 31;11(2):331. doi: 10.4081/oncol.2017.331. eCollection 2017 Jun 14.
3
Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis.乳腺癌肝转移的肝切除术：成本效益分析。
Ann Surg. 2017 Apr;265(4):792-799. doi: 10.1097/SLA.0000000000001715.
4
Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches.高危前列腺癌治疗中的治疗顺序：为多模式个体化治疗方法铺平道路。
Front Oncol. 2021 Aug 4;11:732766. doi: 10.3389/fonc.2021.732766. eCollection 2021.
5
Gadolinium-enhanced arterial-phase MR imaging of hypervascular liver tumors: comparison between tailored and fixed scanning delays in the same patients.
J Magn Reson Imaging. 2000 Mar;11(3):244-9. doi: 10.1002/(sici)1522-2586(200003)11:3<244::aid-jmri2>3.0.co;2-q.
6
Experiences of breast cancer survivors participating in a tailored exercise intervention -a qualitative study.乳腺癌幸存者参与定制化运动干预的体验 - 一项定性研究。
Anticancer Res. 2014 Mar;34(3):1193-9.
7
Highlights from the 15th St Gallen International Breast Cancer Conference 15-18 March, 2017, Vienna: tailored treatments for patients with early breast cancer.2017年3月15日至18日于维也纳举行的第15届圣加仑国际乳腺癌大会亮点：早期乳腺癌患者的个体化治疗。
Ecancermedicalscience. 2017 Apr 7;11:732. doi: 10.3332/ecancer.2017.732. eCollection 2017.
8
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.浸润性乳腺癌的术前治疗：可手术疾病的病理评估及全身治疗问题
J Clin Oncol. 2008 Feb 10;26(5):814-9. doi: 10.1200/JCO.2007.15.3510.
9
Management of liver metastases in colorectal cancer patients: A retrospective case-control study of systemic therapy versus liver resection.结直肠癌患者肝转移的管理：一项全身治疗与肝切除对比的回顾性病例对照研究
Eur J Cancer. 2016 May;59:13-21. doi: 10.1016/j.ejca.2016.02.003. Epub 2016 Mar 16.
10
Nonalcoholic fatty liver disease and alcoholic liver disease: metabolic diseases with systemic manifestations.非酒精性脂肪性肝病和酒精性肝病：具有全身表现的代谢性疾病。
Transl Gastroenterol Hepatol. 2019 Sep 3;4:65. doi: 10.21037/tgh.2019.08.09. eCollection 2019.

本文引用的文献

1
Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis.瑞戈非尼在肝细胞癌患者中的疗效：一项系统评价和荟萃分析。
Cancers (Basel). 2019 Dec 20;12(1):36. doi: 10.3390/cancers12010036.
2
Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib.系统评价与荟萃分析：索拉非尼治疗肝细胞癌患者中皮肤病事件的关键作用。
Aliment Pharmacol Ther. 2019 Mar;49(5):482-491. doi: 10.1111/apt.15088. Epub 2019 Jan 29.
3
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.阿昔替尼对比安慰剂作为肾细胞癌的辅助治疗：来自 III 期、随机对照 ATLAS 试验的结果。
Ann Oncol. 2018 Dec 1;29(12):2371-2378. doi: 10.1093/annonc/mdy454.
4
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study.长期索拉非尼治疗肝细胞癌患者的临床结局：一项多中心真实世界研究。
Future Oncol. 2018 Dec;14(29):3049-3058. doi: 10.2217/fon-2018-0281. Epub 2018 Aug 9.
5
Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study.晚期肝细胞癌患者二线使用阿昔替尼的疗效、安全性及生物标志物的区域差异：来自一项随机II期研究
Liver Cancer. 2018 May;7(2):148-164. doi: 10.1159/000484620. Epub 2017 Dec 8.
6
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.欧洲肝脏研究学会临床实践指南：肝细胞癌的管理
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.
7
AASLD guidelines for the treatment of hepatocellular carcinoma.美国肝病研究学会肝细胞癌治疗指南。
Hepatology. 2018 Jan;67(1):358-380. doi: 10.1002/hep.29086.
8
Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses.中晚期肝细胞癌的经动脉放射性栓塞：系统评价与荟萃分析
Oncotarget. 2016 Nov 1;7(44):72343-72355. doi: 10.18632/oncotarget.11644.
9
Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma.肝癌切除术后肝失代偿相关因素的层次交互作用。
JAMA Surg. 2016 Sep 1;151(9):846-53. doi: 10.1001/jamasurg.2016.1121.
10
Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma.诱导不良事件的耐受性可增加索拉非尼的药物暴露量，并优化晚期肝细胞癌患者的治疗结局。
Liver Int. 2016 Jul;36(7):1033-42. doi: 10.1111/liv.13052. Epub 2016 Jan 20.